Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
08-Jan-2008 -
Pfizer Inc and Taisho Pharmaceutical Co., Ltd. have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop and commercialize TS-032, a new schizophrenia drug candidate ...
central nervous system
CNS disorders
Japan
+4